Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Carboplatin is named as an intervention in 380 current clinical trials in our China, USA, UK, India and Ireland registers. 208 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (44). The most-studied condition is Non-small Cell Lung Cancer.

Trials by status

Recruiting20855%
Not yet open3810%
Active, closed13235%
By invitation21%

Trials by phase

Phase 313034%
Phase 212633%
Phase 1/25214%
Phase 14412%
Phase 2/3205%
Phase 441%
Not applicable31%
Observational10%

Clinical trials of Carboplatin

380 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer NCT06457503 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer Recurrent	Phase 4	Recruiting	Coherus Oncology, Inc.	USA
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. NCT07279935 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 4	Recruiting	AstraZeneca	China
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) NCT01704716 · Neuroblastoma	Phase 3	Recruiting	St. Anna Kinderkrebsforschung	Ireland
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 · ClinicalTrials.gov ↗ · Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 · ClinicalTrials.gov ↗ · Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT NCT04137653 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Shengjing Hospital	China
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT04547907 · ClinicalTrials.gov ↗ · Breast Cancer,HER2-positive	Phase 3	Recruiting	Henan Cancer Hospital	China
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, HER2-expressing	Phase 3	Recruiting	RemeGen Co., Ltd.	China
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial NCT05367206 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemotherapy, Bulky Neoplasm	Phase 3	Recruiting	Sun Yat-sen University	China
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） NCT05429463 · ClinicalTrials.gov ↗ · Squamous Cell Non-small Cell Lung Cancer	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM NCT05902169 · Glioblastoma, Recurrent Glioblastoma, GBM	Phase 3	Recruiting	CarThera	USA
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab	Phase 3	Recruiting	Beijing Tongren Hospital	China
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, India, China
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06279364 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410 · ClinicalTrials.gov ↗ · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer	Phase 3	Recruiting	Allist Pharmaceuticals, Inc.	China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06417814 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277 · Advanced Non-small Cell Lung Cancer, HER2 Mutation	Phase 3	Recruiting	Bayer	UK, USA, China
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% NCT06561386 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc.	USA, China
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer NCT06712355 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · ClinicalTrials.gov ↗ · Melanoma, Cutaneous Malignant	Phase 3	Recruiting	Immatics US, Inc.	UK, USA
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644 · ClinicalTrials.gov ↗ · NSCLC	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	BeBetter Med Inc	China
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06793215 · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	Ireland, UK, USA, China
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs NCT06829459 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc.	China
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Mirati Therapeutics Inc.	Ireland, UK, USA, India, China
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer NCT06915025 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Imunon	USA
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） NCT06927986 · ClinicalTrials.gov ↗ · EGFR-mutated Locally Advanced or Metastatic NSCLC	Phase 3	Recruiting	CSPC Megalith Biopharmaceutical Co.,Ltd.	China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation NCT06956001 · ClinicalTrials.gov ↗ · EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 3	Recruiting	Allist Pharmaceuticals, Inc.	China
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · ClinicalTrials.gov ↗ · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639 · ClinicalTrials.gov ↗ · NSCLC Patients With Brain Metastasis	Phase 3	Recruiting	Allist Pharmaceuticals, Inc.	China
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma NCT07002346 · ClinicalTrials.gov ↗ · Ovarian Clear Cell Carcinoma	Phase 3	Recruiting	Tongji Hospital	China
Omitting CTV for Primary Tumor in LS-SCLC NCT07008716 · ClinicalTrials.gov ↗ · SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect	Phase 3	Recruiting	Sun Yat-sen University	China
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751 · Breast Neoplasms	Phase 3	Recruiting	BioNTech SE	UK, USA, China
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC NCT07178795 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer NCT07276399 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma NCT07371611 · ClinicalTrials.gov ↗ · Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)	Phase 3	Recruiting	Qunxing Li,MD	China
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer NCT07441460 · ClinicalTrials.gov ↗ · Resectable HER2-positive Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc.	China
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy NCT07472517 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 3	Recruiting	Boehringer Ingelheim	Ireland, UK, USA, China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Cancer (epNEC)	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141 · ClinicalTrials.gov ↗ · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	USA
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma	Phase 3	Recruiting	SystImmune Inc.	USA
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer NCT07739758 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer NCT06123884 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2/3	Recruiting	Bio-Thera Solutions	China
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	AbbVie	USA
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer NCT06712316 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	BioNTech SE	UK, USA, China
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102 · ClinicalTrials.gov ↗ · Non-Squamous Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	AbbVie	USA, China
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer With MTAP Deletion	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080 · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy NCT07106762 · Urothelial Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma NCT07129993 · ClinicalTrials.gov ↗ · Urothelial Cancer, Bladder Cancer	Phase 2/3	Recruiting	Daiichi Sankyo	USA, China
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC	Phase 2/3	Recruiting	Eikon Therapeutics	USA
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT07544056 · ClinicalTrials.gov ↗ · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer	Phase 2/3	Recruiting	BeBetter Med Inc	China
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) NCT07642024 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT07662395 · ClinicalTrials.gov ↗ · Double Blind	Phase 2/3	Recruiting	Sinocelltech Ltd.	China
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer NCT04138719 · ClinicalTrials.gov ↗ · Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer NCT04159142 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Nab-paclitaxel	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma NCT05014464 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	AstraZeneca	Ireland, USA
Modified CV Regimen in Optic Pathway Glioma NCT05278715 · ClinicalTrials.gov ↗ · Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma	Phase 2	Recruiting	Beijing Sanbo Brain Hospital	China
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. NCT05351788 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · ClinicalTrials.gov ↗ · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer NCT05498428 · ClinicalTrials.gov ↗ · Carcinoma, Non-small-Cell Lung	Phase 2	Recruiting	Janssen Research & Development, LLC	UK, USA, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer NCT05638594 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer NCT05766800 · ClinicalTrials.gov ↗ · Locally Advanced, Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
AK104 for Recurrent or Metastatic Vulvar Cancer NCT05932212 · ClinicalTrials.gov ↗ · Vulvar Cancer	Phase 2	Recruiting	Akeso	China
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC NCT05941338 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Oral Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC NCT05980702 · ClinicalTrials.gov ↗ · HNSCC, Oral Cancer, PD-1	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative NCT06001151 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Qian Chu	China
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy NCT06084897 · ClinicalTrials.gov ↗ · Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Breast Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC NCT06125041 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer	Phase 2	Recruiting	Qianfoshan Hospital	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery NCT06209294 · ClinicalTrials.gov ↗ · Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery	Phase 2	Recruiting	Xiaohua Wu	China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer NCT06437353 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	Anhui Provincial Cancer Hospital	China
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer NCT06483282 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Jin Ying	China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC NCT06497530 · ClinicalTrials.gov ↗ · Extensive-Stage Small Cell Lung Cancer	Phase 2	Recruiting	Guangzhou Institute of Respiratory Disease	China
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations NCT06514027 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	BeBetter Med Inc	China
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC NCT06532591 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	Sichuan Cancer Hospital and Research Institute	China
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · ClinicalTrials.gov ↗ · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer NCT06561308 · ClinicalTrials.gov ↗ · Endometrioid Endometrial Cancer	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC NCT06637163 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer NCT06734182 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy NCT06868836 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. NCT06890338 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 2	Recruiting	AbbVie	USA
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC NCT06897046 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), II-IIIB	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07023484 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	Phase 2	Recruiting	The University of Hong Kong	China
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784 · ClinicalTrials.gov ↗ · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer	Phase 2	Recruiting	AbbVie	USA
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer NCT07059845 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	AbbVie	USA
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC NCT07098988 · ClinicalTrials.gov ↗ · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer NCT07102381 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687 · ClinicalTrials.gov ↗ · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	Phase 2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer NCT07125391 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	Bai-Rong Xia	China
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer NCT07155174 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	AbbVie	USA, China
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI NCT07181499 · ClinicalTrials.gov ↗ · NSCLC, Adjuvant Drug Therapy, EGFR	Phase 2	Recruiting	Betta Pharmaceuticals Co., Ltd.	China
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · Squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer NCT07229729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer NCT07241767 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) NCT07283692 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment NCT07285941 · ClinicalTrials.gov ↗ · Ovarian Cancer, HER2	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC NCT07309952 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer	Phase 2	Recruiting	Yang Hong	China
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer NCT07353723 · ClinicalTrials.gov ↗ · Head & Neck Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. NCT07394387 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer NCT07396324 · ClinicalTrials.gov ↗ · HR-positive/HER2-negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab NCT07486817 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell	Phase 2	Recruiting	Boehringer Ingelheim	China
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Second Affiliated Hospital of Zunyi Medical University	China
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC NCT07586202 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Janssen Research & Development, LLC	USA, China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT07622186 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. NCT07638852 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer, Brain Metastasases	Phase 2	Recruiting	Fudan University	China
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07646301 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Locally Advanced	Phase 2	Recruiting	Sun Yat-sen University	China
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154 · ClinicalTrials.gov ↗ · HNSCC	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764 · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Bristol-Myers Squibb	UK, USA, China
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC NCT07733830 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005 · Metastatic Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers NCT05098132 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC	Phase 1/2	Recruiting	Synthekine	Ireland, USA
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation NCT05410145 · ClinicalTrials.gov ↗ · KRAS P.G12C	Phase 1/2	Recruiting	D3 Bio (Wuxi) Co., Ltd	USA, China
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775 · ClinicalTrials.gov ↗ · Mature B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Recruiting	Hoffmann-La Roche	USA, China
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 · ClinicalTrials.gov ↗ · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma	Phase 1/2	Recruiting	Genmab	USA, China
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT05739981 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 1/2	Recruiting	Imunon	USA
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation NCT05789082 · Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA, China
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · ClinicalTrials.gov ↗ · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China
Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer	Phase 1/2	Recruiting	Avenzo Therapeutics, Inc.	USA
IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd.	China
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc.	USA
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) NCT06362252 · ClinicalTrials.gov ↗ · Extensive Stage-small Cell Lung Cancer	Phase 1/2	Recruiting	Daiichi Sankyo	USA
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 1/2	Recruiting	Janssen Research & Development, LLC	UK, USA, China
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT06474455 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	LaNova Medicines Limited	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC NCT06754930 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623 · ClinicalTrials.gov ↗ · Non Small Cell Lung Carcinoma	Phase 1/2	Recruiting	AbbVie	UK, USA, China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) NCT06843447 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors NCT06953323 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	China
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	AstraZeneca	USA, China
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Verastem, Inc.	USA
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) NCT07070440 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 1/2	Recruiting	Dizal Pharmaceuticals	China
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC NCT07136285 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Recruiting	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.	China
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer NCT07174583 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3	Phase 1/2	Recruiting	IDEAYA Biosciences	USA
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) NCT07227597 · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer NCT07229599 · ClinicalTrials.gov ↗ · Advanced Lung Cancer	Phase 1/2	Recruiting	Minghui Pharmaceutical (Hangzhou) Ltd	China
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors NCT07287995 · Locally Advanced or Metastatic Malignant Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors NCT07466160 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer NCT07623356 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Akeso	China
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer	Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas NCT03715933 · ClinicalTrials.gov ↗ · Ewing Sarcoma, Colorectal Adenocarcinoma	Phase 1	Recruiting	Inhibrx Biosciences, Inc	UK, USA
A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 · ClinicalTrials.gov ↗ · Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer	Phase 1	Recruiting	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	USA
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 1	Recruiting	AstraZeneca	USA, China
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189 · Non-Small Cell Lung Cancer	Phase 1	Recruiting	BioNTech SE	UK, USA
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation NCT05504278 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer	Phase 1	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer NCT06179069 · ClinicalTrials.gov ↗ · SCLC	Phase 1	Recruiting	Zai Lab (Shanghai) Co., Ltd.	USA, China
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors NCT06384352 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	USA, China
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · ClinicalTrials.gov ↗ · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer	Phase 1	Recruiting	Eli Lilly and Company	USA
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies NCT06839105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	Phase 1	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation NCT06946927 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Jemincare	China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA, China
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors NCT07128303 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Gilead Sciences	USA
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC NCT07178171 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer	Phase 1	Recruiting	Xijing Hospital	China
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07219212 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 1	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	USA
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) NCT04519905 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival	Not applicable	Recruiting	Fudan University	China
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer NCT06234137 · ClinicalTrials.gov ↗ · Breast Neoplasm Female	Not applicable	Recruiting	Wang Ouchen	China
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 4	Not yet open	Peking Union Medical College Hospital	China
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer NCT07093931 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Not yet open	Shandong Cancer Hospital and Institute	China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer NCT06704620 · ClinicalTrials.gov ↗ · Advanced and Metastatic NSCLC	Phase 3	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer NCT07360132 · ClinicalTrials.gov ↗ · Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd.	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer NCT07383116 · ClinicalTrials.gov ↗ · Non Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd.	China
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Not yet open	Bristol-Myers Squibb	USA, India, China
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC NCT07720193 · ClinicalTrials.gov ↗ · Advanced Extrapulmonary Neuroendocrine Carcinoma	Phase 3	Not yet open	Nanjing Leads Biolabs Co.,Ltd	China
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma NCT07827872 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer	Phase 3	Not yet open	caohaotian	China
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer NCT07318883 · Squamous NSCLC	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) NCT07739199 · ClinicalTrials.gov ↗ · Squamous Non-small-cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer NCT05794659 · ClinicalTrials.gov ↗ · Advanced Ovarian Cancer	Phase 2	Not yet open	Aston Sci. Inc.	USA
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer NCT05983094 · ClinicalTrials.gov ↗ · Breast Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck NCT06016413 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer NCT06109402 · ClinicalTrials.gov ↗ · Stage II-IIIB(N2) Non-small Cell Lung Cancer	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Myeloprotection With Trilaciclib in Pan-cancer Population NCT06297811 · Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer NCT06404736 · ClinicalTrials.gov ↗ · Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC NCT06688656 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Not yet open	Shanghai Chest Hospital	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer NCT06751277 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Endometrial Cancer	Phase 2	Not yet open	xiang yang	China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer NCT06786312 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	Fujian Cancer Hospital	China
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC NCT06837948 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer. NCT07083375 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer	Phase 2	Not yet open	Zhijie Wang	China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. NCT07136974 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Henan Cancer Hospital	China
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer NCT07246317 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study NCT07365410 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients NCT07493980 · ClinicalTrials.gov ↗ · NSCLC Stage II	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer NCT07663513 · ClinicalTrials.gov ↗ · Ovarian Cancers	Phase 2	Not yet open	Fudan University	China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
Perioperative Adebrelimab for Locally Advanced Cervical Cancer NCT07811375 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Not yet open	Anhui Provincial Hospital	China
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Not yet open	Tongji Hospital	China
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. NCT07559929 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 1/2	Not yet open	Hangzhou DAC Biotechnology Co., Ltd.	China
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT07612137 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd.	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd.	China
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd.	China
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Not yet open	Fuzhou General Hospital	China
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. NCT06649448 · ClinicalTrials.gov ↗ · Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF	Not applicable	Not yet open	Shandong Cancer Hospital and Institute	China
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. NCT06281964 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer	Phase 3	By invitation	Avistone Biotechnology Co., Ltd.	China
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） NCT06910072 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy	Phase 2/3	By invitation	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer NCT01566240 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	University College, London	India
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma NCT01820858 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Ding Ma	China
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · ClinicalTrials.gov ↗ · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) NCT02453282 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer NCT02516241 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) NCT02542293 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) NCT03003962 · ClinicalTrials.gov ↗ · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China
Paediatric Hepatic International Tumour Trial NCT03017326 · ClinicalTrials.gov ↗ · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer NCT03036098 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	USA, China
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) NCT03043872 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma Extensive Disease	Phase 3	Active, closed	AstraZeneca	USA, China
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). NCT03164616 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, China
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer NCT03168880 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Active, closed	Tata Memorial Hospital	India
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients NCT03390686 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer	Phase 3	Active, closed	Prestige Biopharma Limited	India
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer NCT03456076 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer NCT03682068 · Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients NCT03737643 · ClinicalTrials.gov ↗ · Advanced Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	USA, China
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer NCT03800134 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	BeiGene	China
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer NCT03981796 · ClinicalTrials.gov ↗ · Neoplasms	Phase 3	Active, closed	Tesaro, Inc.	UK, USA
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04095364 · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma	Phase 3	Active, closed	NRG Oncology	Ireland
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations NCT04129502 · ClinicalTrials.gov ↗ · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Takeda	UK, USA, China
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer NCT04193059 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Fudan University	China
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer NCT04194944 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Eli Lilly and Company	UK, China
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer NCT04223856 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc.	UK, USA, China
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer NCT04269200 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	AstraZeneca	USA, India, China
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) NCT04296175 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 3	Active, closed	Fudan University	China
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer NCT04351555 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · ClinicalTrials.gov ↗ · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery NCT04498117 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Active, closed	CanariaBio Inc.	USA, India
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions NCT04538664 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, India, China
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Triple Negative Breast Cancer	Phase 3	Active, closed	GBG Forschungs GmbH	Ireland
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations NCT04695925 · ClinicalTrials.gov ↗ · Non-small Cell Carcinoma, EGFR Gene Mutation	Phase 3	Active, closed	Li Zhang, MD	China
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline NCT04723875 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Cervical Cancer	Phase 3	Active, closed	Huazhong University of Science and Technology	China
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) NCT04765059 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, China
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) NCT04956692 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure NCT04988295 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, India, China
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations NCT05048797 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer NCT05091567 · Small-Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer NCT05116462 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Innovent Biologics (Suzhou) Co. Ltd.	China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment NCT05261399 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	AstraZeneca	UK, USA, China
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) NCT05374512 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382299 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, PD-L1 Negative	Phase 3	Active, closed	Gilead Sciences	UK, USA, China
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) NCT05668988 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Dizal Pharmaceuticals	USA, China
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations NCT05687266 · NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients NCT05870319 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. NCT05984277 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · ClinicalTrials.gov ↗ · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment NCT06151574 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell	Phase 3	Active, closed	Boehringer Ingelheim	UK, USA, China
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) NCT06305754 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, India, China
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) NCT06382116 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features NCT06564844 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06711900 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Immutep S.A.S.	Ireland, UK, USA, India
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer NCT06747338 · ClinicalTrials.gov ↗ · Early or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Shanghai JMT-Bio Inc.	China
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer	Phase 3	Active, closed	Amgen	USA, China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Active, closed	Caigang Liu	China
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Active, closed	Regeneron Pharmaceuticals	USA
PhII ICb With/Without Erbitux in MBC Pts NCT00248287 · Metastatic Breast Cancer	Phase 2	Active, closed	US Oncology Research	USA
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer NCT01081951 · Ovarian Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
9-ING-41 in Patients With Advanced Cancers NCT03678883 · ClinicalTrials.gov ↗ · Cancer, Pancreatic Cancer, Sarcoma	Phase 2	Active, closed	Actuate Therapeutics Inc.	USA
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) NCT03775486 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) NCT03944772 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China NCT04015778 · Non Small Cell Lung Cancer	Phase 2	Active, closed	Guangdong Association of Clinical Trials	China
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer NCT04736173 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer	Phase 2	Active, closed	Arcus Biosciences, Inc.	USA
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Akeso	China
Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) NCT04764227 · ClinicalTrials.gov ↗ · Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy	Phase 2	Active, closed	Fudan University	China
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC NCT05189730 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Sichuan Cancer Hospital and Research Institute	China
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer NCT05456685 · ClinicalTrials.gov ↗ · High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer	Phase 2	Active, closed	AbbVie	UK, USA
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer NCT05605535 · Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms	Phase 2	Active, closed	CanariaBio Inc.	India
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · ClinicalTrials.gov ↗ · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer NCT05635708 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer	Phase 2	Active, closed	BeiGene	USA, China
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC NCT05756972 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Biotheus Inc.	China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Active, closed	Sichuan University	China
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC NCT05894889 · ClinicalTrials.gov ↗ · Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer	Phase 2	Active, closed	Peking University	China
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation NCT05975307 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS NCT06008093 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	AstraZeneca	USA
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Regeneron Pharmaceuticals	USA
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations NCT06194448 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, China
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) NCT06225596 · ClinicalTrials.gov ↗ · Metastatic Urothelial Cancer	Phase 2	Active, closed	BicycleTx Limited	UK, USA, China
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC NCT06246110 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Eikon Therapeutics	USA
Volrustomig Priming Regimens Exploratory Phase II Platform Study NCT06448754 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, China
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy NCT06449209 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer	Phase 2	Active, closed	BioNTech SE	UK, USA
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy NCT06449222 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers	Phase 2	Active, closed	BioNTech SE	UK, USA
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) NCT06618014 · ClinicalTrials.gov ↗ · Breast Cancer, Triple Negative Breast Cancer	Phase 2	Active, closed	Sun Yat-sen University	China
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 NCT06727565 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Gilead Sciences	UK, USA, China
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) NCT06946797 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Bristol-Myers Squibb	USA
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer NCT07005336 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	TJ Biopharma Co., Ltd.	China
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 1/2	Active, closed	Imunon	USA
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer NCT03473743 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 1/2	Active, closed	Janssen Research & Development, LLC	UK, USA, China
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · ClinicalTrials.gov ↗ · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies NCT04644068 · ClinicalTrials.gov ↗ · Ovarian Cancer, Breast Cancer, Pancreatic Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, China
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms	Phase 1/2	Active, closed	Eli Lilly and Company	USA
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer	Phase 1/2	Active, closed	Akeso	China
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC NCT06477523 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Active, closed	Sichuan University	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents NCT02264678 · ClinicalTrials.gov ↗ · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	Phase 1	Active, closed	AstraZeneca	UK, USA
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer NCT02609776 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA, China
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) NCT02817633 · Neoplasms	Phase 1	Active, closed	Tesaro, Inc.	USA
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors NCT03530397 · ClinicalTrials.gov ↗ · Selected Advanced Solid Tumors	Phase 1	Active, closed	MedImmune LLC	USA
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC NCT03819465 · ClinicalTrials.gov ↗ · Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 · ClinicalTrials.gov ↗ · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors NCT03893955 · ClinicalTrials.gov ↗ · Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC)	Phase 1	Active, closed	AbbVie	USA, China
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer NCT04077463 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 1	Active, closed	Janssen Research & Development, LLC	USA, China
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) NCT04526691 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC	Phase 1	Active, closed	Daiichi Sankyo	USA
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer NCT04612751 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC	Phase 1	Active, closed	AstraZeneca	USA
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT05117476 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, NSCLC	Phase 1	Active, closed	Cullinan Therapeutics Inc.	USA
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC NCT05595460 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 1	Active, closed	RayzeBio, Inc.	USA
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors NCT05599984 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	AbbVie	USA, China
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer NCT06077500 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma (SCLC)	Phase 1	Active, closed	Boehringer Ingelheim	USA
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). NCT06333951 · ClinicalTrials.gov ↗ · Thoracic Tumors, Non-small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, China
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer NCT07009457 · ClinicalTrials.gov ↗ · Widespread Small Cell Lung Cancer	Phase 1	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Carboplatin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Carboplatin on the HPRA medicines list.

Carboplatin 10 mg/ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/032/001 · Marketed
Carboplatin-Teva 10 mg/ml Concentrate for Solution for InfusionTeva Pharma B.V. · PA0749/004/001 · Marketed
Carboplatin 10 mg/ml concentrate for solution for infusionAccord Healthcare Ireland Ltd. · PA2315/080/001 · Not marketed

All 3 Irish products →

Supply shortages

Carboplatin InjectionUS (FDA) · Current · updated 17 Sep 2026
Carboplatin Accord 10 mg/ml Konzentrat zur Herstellung einer InfusionslösungGermany (BfArM) · Production problem · 15 May 2026 to 30 Nov 2026

EU shortages US shortages German shortages

Conditions studied with Carboplatin

315 conditions

Non-small Cell Lung Cancer28 Non-Small Cell Lung Cancer24 Ovarian Cancer20 Breast Cancer18 Carcinoma, Non-Small-Cell Lung17 Non Small Cell Lung Cancer10 NSCLC10 Fallopian Tube Cancer10 Advanced Solid Tumors10 Triple Negative Breast Cancer9 Advanced Solid Tumor8 Cervical Cancer8

All 315 conditions

Condition (as registered)	Trials
Non-small Cell Lung Cancer	28
Non-Small Cell Lung Cancer	24
Ovarian Cancer	20
Breast Cancer	18
Carcinoma, Non-Small-Cell Lung	17
Non Small Cell Lung Cancer	10
NSCLC	10
Fallopian Tube Cancer	10
Advanced Solid Tumors	10
Triple Negative Breast Cancer	9
Advanced Solid Tumor	8
Cervical Cancer	8
Endometrial Neoplasms	7
Ovarian Neoplasms	6
Head and Neck Squamous Cell Carcinoma	6
Lung Cancer	6
Solid Tumor	6
Urothelial Cancer	5
Endometrial Cancer	5
Esophageal Squamous Cell Carcinoma	5
Small-cell Lung Cancer	5
Neoadjuvant Therapy	5
Urothelial Carcinoma	4
Squamous Cell Carcinoma of Head and Neck	4
Breast Neoplasms	4
Primary Peritoneal Cancer	4
Extensive-stage Small-cell Lung Cancer	4
Metastatic Non-small Cell Lung Cancer	4
Non-squamous Non-small Cell Lung Cancer	4
Colorectal Cancer	4
Small Cell Lung Cancer Extensive Stage	4
Non-small Cell Lung Cancer (NSCLC)	4
Epithelial Ovarian Cancer	4
Neoplasm Metastasis	3
Metastatic Urothelial Cancer	3
Neoplasms	3
Pancreatic Ductal Adenocarcinoma	3
Uterine Cervical Neoplasms	3
HER2-positive Breast Cancer	3
Primary Peritoneal Carcinoma	3
Triple-Negative Breast Cancer (TNBC)	3
Small Cell Lung Cancer	3
NSCLC (Advanced Non-small Cell Lung Cancer)	3
TNBC, Triple Negative Breast Cancer	3
SCLC, Extensive Stage	3
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	2
Small Cell Lung Carcinoma	2
Small Cell Lung Cancer (SCLC)	2
Fallopian Tube Neoplasms	2
HER2-negative Breast Cancer	2
Germ Cell Tumor	2
Extensive-Stage Small Cell Lung Cancer	2
Metastatic Breast Cancer	2
Small-Cell Lung Cancer	2
Non Small Cell Lung Carcinoma NSCLC	2
Metastatic Non-Small Cell Lung Cancer (NSCLC)	2
Triple Negative Breast Neoplasms	2
Colorectal Adenocarcinoma	2
Colorectal Neoplasms	2
Melanoma	2
Non-Small-Cell Lung Cancer	2
Pancreatic Cancer	2
Lung Cancer, Non-squamous, Non-small Cell	2
Squamous Non-small Cell Lung Cancer	2
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2
Advanced or Metastatic NSCLC	2
Bladder Cancer	2
Platinum-Sensitive Ovarian Cancer	2
Peritoneal Cancer	2
Cancer	2
Advanced Ovarian Cancer	2
Advanced or Metastatic Non-small Cell Lung Cancer	2
Oral Squamous Cell Carcinoma (OSCC)	2
Locally Advanced	2
Extensive Small Cell Lung Cancer	2
EGFR	2
Chemoradiotherapy	2
Head & Neck Cancer	2
Locally Advanced Non-Small Cell Lung Cancer	2
Head and Neck Squamous Cell Carcinoma (HNSCC)	2
HNSCC	2
Oral Cancer	2
Triple-negative Breast Cancer	2
Nab-paclitaxel	2
Untreated Advanced NSCLC	1
1st Line NSCLC	1
Low Grade Fallopian Tube Serous Adenocarcinoma	1
Ovarian Low Grade Serous Adenocarcinoma	1
Primary Peritoneal Low Grade Serous Adenocarcinoma	1
Stage II Fallopian Tube Cancer AJCC v8	1
Neuroblastoma	1
KRAS G12C Lung Cancer	1
Hepatoblastoma	1
Carcinoma, Hepatocellular	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
Peritoneal Neoplasms	1
Teratoma	1
Choriocarcinoma	1
Germinoma	1
Solid Tumors	1
Advanced Non-small Cell Lung Cancer, HER2 Mutation	1
Carcinoma, Non-Small Cell Lung	1
HER2 Negative Breast Neoplasms	1
High Grade Ovarian Cancer	1
PD-L1 Positive	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
PD-L1 Negative	1
Non-small Cell Lung Cancer NSCLC	1
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	1
Ewing Sarcoma	1
Exocrine Pancreatic Cancer	1
Carcinoma, Squamous Cell of Head and Neck	1
Metastatic Non-small Cell Lung Cancer With MTAP Deletion	1
Metastatic Non Small Cell Lung Cancer	1
Extrapulmonary Neuroendocrine Cancer (epNEC)	1
Gastric Cancer	1
Metastatic Castration-resistant Prostate Cancer	1
Advanced or Metastatic Non-Small-Cell Lung Cancer	1
Resectable Non-Small-Cell Lung Cancer	1
Melanoma, Cutaneous Malignant	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Malignant Solid Tumor	1
Non-Small Cell Lung Cancer (NSCLC)	1
Colorectal Cancer (CRC)	1
Unresectable Pleural Mesothelioma	1
Non Small Cell Lung Cancer NSCLC	1
Carcinoma	1
Non-Small-Cell Lung	1
Carcinoma, Non-small-Cell Lung	1
Lung Neoplasms	1
Lung Adenocarcinoma	1
Lung Squamous Cell Carcinoma	1
Locally Advanced Breast Cancer	1
Metastatic Triple Negative Breast Cancers	1
Prostate Cancer	1
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer	1
Non Small Cell Lung Carcinoma	1
Ovarian Cancer Recurrent	1
HR+/HER2- Breast Cancer	1
HR+, HER2-, Advanced Breast Cancer	1
CCNE1 Amplification	1
Solid Tumor, Adult	1
Glioblastoma	1
Recurrent Glioblastoma	1
GBM	1
Carcinoma, Ovarian Epithelial	1
Ovarian Serous Adenocarcinoma	1
Unresectable Locally Advanced Urothelial Cancer	1
Recurrent Head and Neck Squamous Cell Carcinoma	1
Locally Advanced or Metastatic Malignant Solid Tumors	1
Lung Neoplasm Malignant	1
Extensive Stage Small-cell Lung Cancer	1
Selected Advanced Solid Tumors	1
SCLC,Extensive Stage	1
Non-Small-Cell Lung Carcinoma NSCLC	1
Non-Small Cell Lung Cancer, NSCLC	1
KRAS, NRAS, HRAS-mutated NSCLC	1
KRAS G12C-mutated Solid Tumors, Lung Cancer	1
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Brain Metastases, Adult	1
Small Cell Lung Carcinoma (SCLC)	1
Non-Squamous Non-Small Cell Lung Cancer	1
Neuroendocrine Carcinomas	1
Solid Tumor Show to Express DLL3	1
Mature B-Cell Non-Hodgkin Lymphoma	1
PDAC - Pancreatic Ductal Adenocarcinoma	1
CRC (Colorectal Cancer)	1
Biliary Tract Cancer	1
Cholangiocarcinoma	1
Gynecologic Cancers	1
Primary Peritoneal Cancer (PSOC)	1
Small Cell Lung Carcinoma Extensive Disease	1
Neoadjuvant	1
Small Cell Carcinoma	1
Sclc	1
Metastatic Solid Tumor	1
SMARCA4-Deficient Tumor	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Nonsquamous Non Small Cell Lung Cancer	1
Squamous Non Small Cell Lung Cancer	1
Extensive Stage Small Cell Lung Cancer	1
Thoracic Tumors	1
Resectable Non-small Cell Lung Cancer	1
SCLC	1
Sarcoma	1
Renal Cancer	1
High Grade Epithelial Ovarian Cancer	1
High Grade Serous Ovarian Cancer	1
Locally Advanced or Metastatic Solid Tumors	1
Extensive Stage-small Cell Lung Cancer	1
Non Small Cell Lung Cancer (Squamous or Non Squamous)	1
Stage 4 NSCLC	1
KRAS P.G12C	1
Non-small-cell-lung-cancer (NSCLC)	1
Nasopharyngeal Cancer Recurrent	1
Ovarian Neoplasm Epithelial	1
Peritoneal Carcinoma	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Malignant Germ Cell Tumor	1
Squamous NSCLC	1
Early-stage Oral Cancer	1
Recurrent or Metastatic Endometrial Cancer	1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma	1
Squamous Non-small-cell Lung Cancer	1
Non-squamous NSCLC	1
Locally Advanced Oral Squamous Cell Carcinoma	1
Advanced Non-small-cell Lung Cancer	1
HR-positive/HER2-negative Breast Cancer	1
Early Breast Cancer	1
II-IIIB	1
Pancreatic Ductal Adenocarcinoma (mPDAC)	1
Ovarian Clear Cell Carcinoma	1
Locally Advanced Triple-negative Breast Cancer	1
Metastatic Triple-negative Breast Cancer	1
NSCLC Patients With Brain Metastasis	1
Advanced Non-small Cell Lung Cancer	1
Pembrolizumab	1
Advanced Breast Cancer	1
Brain Metastases	1
Furmonertinib	1
EGFR Mutation	1
HER2-expressing	1
Endometrioid Endometrial Cancer	1
Solid Tumor Cancer	1
Chemotherapy Induced Neutropenia	1
G-CSF	1
Advanced Lung Cancer	1
Squamous Cell Non-small Cell Lung Cancer	1
Salivary Gland Carcinoma	1
Precision Therapy	1
HER2	1
Recurrent or Metastatic Cervical Cancer	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
Non-small Cell Carcinoma	1
EGFR Gene Mutation	1
Survival	1
Ovarian Cancers	1
Resectable HER2-positive Breast Cancer	1
Brain Metastasases	1
Double Blind	1
SCLC, Limited Stage	1
Radiation Exposure	1
Radiotherapy Side Effect	1
Progression	1
Stage IIIb Non-small Cell Lung Cancer	1
Stage IIIC Non-Small Cell Lung Cancer	1
Esophageal Cancer	1
Extensive-stage Small Cell Lung Cancer	1
Ovarian Germ Cell Cancer	1
Ovarian Sex Cord Stromal Tumor	1
Vulvar Cancer	1
Neoadjuvant Chemotherapy	1
Bulky Neoplasm	1
Malignant Solid Tumors	1
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	1
PD-1	1
Recurrent Non-small Cell Lung Cancer	1
Esophageal Squamous Cell Carcinoma (ESCC)	1
Breast Neoplasm Female	1
Advanced Malignant Tumors	1
Early or Locally Advanced HER2-positive Breast Cancer	1
NSCLC Stage II	1
Endometrial Carcinoma	1
TP53 Mutation	1
Recurrent or Metastatic	1
Stage II-IIIB(N2) Non-small Cell Lung Cancer	1
Non Squamous Non-small Cell Lung Cancer	1
Breast Neoplasm	1
Breast Tumors	1
Locally Advanced Cervical Cancer	1
Neoadjuvant Immunotherapy	1
Fertility-sparing Surgery	1
Small Cell Lung Cancer Limited Stage	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Widespread Small Cell Lung Cancer	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Stage IIIB(N2) Non-small Cell Lung Cancer	1
Stage IIA Non-small Cell Lung Cancer	1
Stage IIB Non-small Cell Lung Cancer	1
Stage IIIA Non-small Cell Lung Cancer	1
HER2-positive Early Breast Cancer	1
Optic Glioma	1
Pediatric Brain Tumor, Optic Nerve Glioma	1
Triple Negative Breast Cancer (TNBC)	1
Advanced and Metastatic NSCLC	1
Esophageal Neoplasm Metastatic	1
Esophageal Cancer Stage IVb	1
Breast Cancer,HER2-positive	1
Muscle-Invasive Bladder Carcinoma	1
Programmed Cell Death Protein 1 Inhibitor	1
Radiotherapy	1
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	1
Advanced Non-Small Cell Lung Cancer	1
HER2 + Breast Cancer	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
Adjuvant Drug Therapy	1
Esophagus Cancer	1
Radiation Therapy	1
EGFR-mutated Locally Advanced or Metastatic NSCLC	1
Solid Cancer	1
Advanced Extrapulmonary Neuroendocrine Carcinoma	1
Advanced Non-squamous Non-small-cell Lung Cancer	1
Metastatic Non-squamous Non Small Cell Lung Cancer	1
Head and Neck Cancer	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1

By country register

Register	Trials	Recruiting
Clinical trials in China	282	161
Clinical trials in USA	197	101
Clinical trials in UK	91	45
Clinical trials in India	36	15
Clinical trials in Ireland	23	14

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Carboplatin trials

How many clinical trials are testing Carboplatin?

380 current trials in our China, USA, UK, India and Ireland registers name Carboplatin (also registered as Carboplatin AUC-5) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Carboplatin trials recruiting patients?

Yes. 208 of the 380 trials are recruiting: 161 with sites in China, 101 with sites in USA, 45 with sites in UK, 15 with sites in India and 14 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Carboplatin clinical trials?

AstraZeneca (44), Merck Sharp & Dohme LLC (23), Bristol-Myers Squibb (12) and AbbVie (10), among 161 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Carboplatin licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Carboplatin, for example Carboplatin 10 mg/ml concentrate for solution for infusion (Fresenius Kabi Deutschland GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Carboplatin shortage?

The registers we track list 2 entries for Carboplatin: US FDA: current; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Carboplatin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Carboplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Carboplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Carboplatin clinical trials